document.doc

Alok Chandra Bharti, Ph.D.Scientist D

Institute of Cytology and Preventive Oncology (ICMR)I-7, Sector-39, Noida, Utter Pradesh 201 301, INDIA Tel: +91-120-2575838, Fax: 91-120-2579473;2578838Email: bhartiac@icmr.org.in

Education:Certificate/ Degree Board/

University

Year Subjects Distinctions

B.Sc. Honours University of Delhi, Delhi

1994 Main: Zoology Subsidiaries: Botany and Chemistry

-

M.Sc. University of Delhi, Delhi

1996 ZoologySpecialization Immunology, Cell Biology

Biochemistry, Molecular Biology of Prokaryotes and Eukaryotes

GraduateAptitude Test Examination

Indian Institute of Science, Bangalore

1996 Life Sciences Qualified

National Eligibility Test

Joint CSIR-UGC, New Delhi

1996 Life Sciences Qualified for JRFship and Lecturereship

Ph. D. Banaras Hindu University, Varanasi

1999 BiotechnologyTitle of the thesis: Effect of tumor gangliosides on immune system

PERSONAL VITAE

Date and place of Birth : July 07, 1974, New Delhi

Nationality : Indian

State of Domicile : New Delhi

Marital status : Married, Two children

Residence:

Bharti Sadan, 40/1362 D.D.A. Flats, Sector-3, Madangir, New Delhi-110 062, India

Telephone: +91-11-2995-6826, Mobile: +91-921 123 0221

- 1 -

document.doc

RESEARCH AND PROFESSIONAL EXPERIENCE

2008 Mar -onwards Scientist D (Assistant Director), Institute of Cytology and

Preventive Oncology, Sector-39, NOIDA, Utter Pradesh, India

2004 May -2008 Mar Senior Research Officer (Scientist C), Institute of Cytology and

Preventive Oncology, Sector-39, NOIDA, Utter Pradesh, India

2003 Aug-May 2004 Senior Research Officer, Department of Transplant Immunology

and Immunogenetics, All India Institute of Medical Sciences, New

Delhi, India

2001 Jun-2003 Jun Postdoctoral Fellow, The University of Texas MD Anderson

Cancer Center, Houston, USA

2001 Jan-2001 May Project Associate, National Institute of Immunology, New Delhi, India

2000 Feb-2000 Dec Senior Research Fellow, Center for Biochemical Technology, New

Delhi, India

1999 Jan -2000 Feb Senior Research Fellow, Banaras Hindu University, Varanasi, India

1996 Dec-1998 Dec Junior Research Fellow, Banaras Hindu University, Varanasi, India.

Publications (Total - 21; Research Articles - 17 & Book Chapters - 4)

1. Mishra, A., Bharti, A.C., Varghese, P., Saluja D., and Das, B.C. (2006). Differential expression and activation of NF-B family proteins during oral carcinogenesis: Role of high risk human papillomavirus infection. International Journal of Cancer (In Press).

2. Das, B.C., Sarin, S.K., Kazim, S.N., and Bharti, A.C. (2006). Infections Causing Cancer. In UICC handbook – Cancer awareness, Prevention and control strategies (Ed. Dr. S Shastri), UICC Press, Geneva, Switzerland.

3. Bharti, A.C., Takada, Y., and Aggarwal, B.B. (2005). PARP Cleavage and Caspase Activity to Assess Chemosensitivity. In Methods in Molecular Medicine: Chemosensitivity (Ed. Dr. R. Blumenthal), Humana Press, NJ, USA 111: 69-78. [Pubmed]

4. Aggarwal, B.B., Bharti, A.C., and Shishodia., S. (2005).Tumor Necrosis Factor and its Family Members. In Protein Discovery Ed Arap, W., Salvesen, G., and Dixit, V.M.

- 2 -

document.doc

5. Bharti, A.C., and Aggarwal, B.B. (2004). Ranking the role of RANK ligand in apoptosis. Apoptosis 9:677-690. [Pubmed]

6. Bharti, A.C., Takada, Y., and Aggarwal, B.B. (2004). Curcumin (Diferuloylmethane) inhibits receptor activator of NF-kappaB ligand-induced NF-kappaB activation in osteoclast precursors and suppresses osteoclastogenesis. Journal of Immunology 172: 5940-5947. [Pubmed]

7. Zheng, B., Georgakis, G.V., Li, Y., Bharti, A., McConkey, D., Aggarwal, B.B., and Younes, A. (2004). Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-B mutations or activation of the CD30, CD40, and RANK receptors. Clinical Cancer Research 10: 3207–3215. [Pubmed]

8. Bharti, A.C., Shishodia, S., Reuben, J.M., Weber, D., Alexanian, R., Raj-Vadhan, S., Estrov, Z., Talpaz, M., and Aggarwal, B.B. (2004). Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103: 3175-84. [Pubmed]

9. Bharti, A.C., Takada, Y., Shishodia, S., and Aggarwal, B.B. (2004). Evidence that receptor activator of nuclear factor (NF)-kappaB ligand can suppress cell proliferation and induce apoptosis through activation of a NF-kappaB-independent and TRAF6-dependent mechanism. Journal of Biological Chemistry 279: 6065-76. [Pubmed]

10. Aggarwal, B.B., Kumar, A., and Bharti, A.C. (2004) Therapeutic Potential of Curcumin Derived from Turmeric (Curcuma longa). In “Herbal and Traditional Medicine: Molecular Basis of Health”. Eds. Packer, L., Nam Ong, C. and Halliwell, B.

11. Bharti, A.C., Donato, N., and Aggarwal, B.B. (2003) Curcumin (Diferuloylmethane) inhibits constitutive and interleukin-6-inducible STAT3 phosphorylation in human multiple myeloma cells: Relationship to Suppression of proliferation. Journal of Immunology 171: 3863-3871. [Pubmed]

12. Bharti, A.C., Donato, N., Singh, S., and Aggarwal, B.B. (2003) Curcumin (diferuloylmethane) downregulates the constitutive activation of nuclear factor-kappaB and IkappaB alpha kinase in human multiple myeloma cells leading to suppression of proliferation and induction of apoptosis. Blood 101: 1053-1062.[Pubmed]

13. Aggarwal, B.B., Kumar, A., and Bharti, A.C. (2003) Anticancer Potential of Curcumin: Preclinical and Clinical Studies. Anticancer Research 23: 363-398.[Pubmed]

14. Bharti, A.C., and Singh S.M. (2003). Inhibition of macrophage nitric oxide production by gangliosides derived from T cell lymphoma: Involved mechanism(s). Nitric oxide: Biology and Chemistry 8: 75-82. [Pubmed]

15. Aggarwal, B.B., Bharti, A.C., Ashikawa, K., and Aggarwal, S (2003). Identification of blockers of transcription factors NF-kappaB from natural

- 3 -

document.doc

sources: potential role in suppression of inflammation and cancer. Proceedings: Symposium on Molecular Medicine (ed. by C.N. Ramchand).

16. Ashikawa, K., Majumdar, S., Banerjee, S., Bharti, A.C., and Aggarwal, B.B. (2002). Trans-3,4,3’,5’-tetrahydroxystilbene (piceatannol) inhibits TNF-induced nuclear Factor-kappaB activation through suppression of IkappaB alpha kinase and p65 phosphorylation. Journal of Immunology 169: 6490-6497.[Pubmed]

17. Bharti, A.C., and Aggarwal, B.B. (2002). Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochemical Pharmacology 64: 883-888.[Pubmed]

18. Aggarwal, B.B., Shishodia, S., Ashikawa, K. and Bharti, A.C. (2002). The Role of TNF and its family members in inflammation and cancer: lessons from gene deletion. Current Drug Targets: Inflammation and Allergy 1: 327-341. [Pubmed]

19. Bharti, A.C., and Aggarwal, B.B (2002). Chemopreventive agents induce suppression of nuclear factor-kappa B leading to chemosensitization. Annals of the New York Academy of Sciences on Cell Signaling, Transcription and Translation as Therapeutic Agents 973: 392-395.[Pubmed]

20. Bharti, A.C., and Singh, S.M. (2001). Gangliosides derived from a T cell lymphoma inhibit bone marrow cell proliferation and differentiation. International Immunopharmacology 1: 155-165.[Pubmed]

21. Bharti, A.C., and Singh, S.M. (2000). Induction of apoptosis in bone marrow cells by gangliosides produced by a T cell lymphoma. Immunology Letters 72: 39-48.[Pubmed]

Abstracts (32)1.Rashmi Singhai, Sutapa Mahata, Bhupesh K. Prusty, Alok C. Bharti and Bhudev C. Das

“Effect of Phyllanthus amarus extract on AP-1 activity in cervical cancer cells.” 27th

Annual Convention Of Indian Association For Cancer Research,Networking Research to Applications & INTERNATIONAL SYMPOSIUM ON Frontiers in Functional Genomics Feb. 6 – 9 , 2008.

2.Shirish Shukla, Prishla Varghese, Sutapa Mahata, Showket Husain, Suresh Hedau, Seemi. F. Bashir, Bhudev C Das, Alok C Bharti. “Aberrant Expression and activation of Transcription factor STAT3 in cervical carcinogenesis.” 27th Annual Convention Of Indian Association For Cancer Research,Networking Research to Applications & INTERNATIONAL SYMPOSIUM ON Frontiers in Functional Genomics Feb. 6 – 9 , 2008.

3.Showket Hussain, Irfana Salam, Suresh Hedau, Mohammad Akbar Bhat, Mohammad M. Mir, Mushtaq A. Siddiqi, Seemi Farhat Basir, Alok C. Bharti, Bhudev C. Das. “The role of Activator Protein (AP-1) in the Pathogenesis of Esophageal Cancer.” 27 th Annual Convention Of Indian Association For Cancer Research,Networking Research to Applications & INTERNATIONAL SYMPOSIUM ON Frontiers in Functional Genomics Feb. 6 – 9 , 2008.

- 4 -

document.doc

4.Rakesh Kumar, Aswini Gnanasekaran, Suresh Hedau, Prishla Varghese, Alok C. Bharti, Madan M. Chaturvedi and Bhudev C. Das. “Trans-activation and expression profiling of different members of AP-1 transcription factors in Breast Carcinogenesis.” 27th Annual Convention Of Indian Association For Cancer Research,Networking Research to Applications & INTERNATIONAL SYMPOSIUM ON Frontiers in Functional Genomics Feb. 6 – 9 , 2008.

5.Sutapa Mahata, Shirish Shukla, Saurabh Maru, Suresh Hedau, Alok C. Bharti, Mausumi Bharadwaj and Bhudev C. Das. “Early Detection of Human Papillomavirus and Control of Cervical Cancer.” Sciences Congress, Visakhapatnam, Jan 3-7, 2008

6.Showket Hussain, Shirish Shukla, Umesh Kumar, Abhishek Tyagi, Sutapa Mahata, Rakesh Kumar, Prishla Varghese, Harsimrut Kaur, Anita Sharma, Suresh Hedau, Mausumi Bharadwaj, Alok C. Bharti, J. K. Sharma, Bhudev C Das. High Prevalence of specific cancers in North-East India: Effect of environmental agents. International Symposium on the Predictive, Preventive and Mechanistic Mutagensis & XXXIII EMSI Annual Meeting, Aligharh Muslim University (AMU), Aligharh. Jan 1-3, 2008.

7.Harsimrut Kaur, Prishla Varghese, Alok C Bharti and Bhudev C Das. Genomics: Deciphering the Molecular Signature of Genes in Pathogenesis of Cervical Cancer. XIIIth All India Congress of Cytology and Genetics & International Symposium on “Genomic and Proteomic Approaches to Decipher the Molecular Basis of Pathogenesis”, Dept. of Zoology, Osmania University, Hyderabad, Dec 28-30, 2007.

8.Shirish Shukla, Suresh Hedau, Showket Hussain, Rakesh Kumar, Abhishek Tyagi, Shailja Pande, Prishla Varghese, Harsimrut Kaur, Alok C. Bharti, Mausumi Bharadwaj and B.C. Das. “Biology of HPV and Human Cancer” in 34th National Conference of Association of Clinical Biochemists of India held at India Habitat Center, New Delhi during 17 th -20th

December, 2007.

9.S. Mahata, A. Mishra, S Shukla, S Hussain, S Maru, R Kumar, A Tyagi, S Hedau, AC Bharti, BC Das. “Transcriptional Targeting of Epithelial Cell Carcinoma by Herbal Derivatives” International Symposium on Translational Cancer Research, Lonavala, Mumbai, December 9-12, 2007.

10. S. Shukla, S. Mahata, BK Prusty, S Hedau, BC Das and Alok C. Bharti. “Transcriptional Targeting of STAT3 in Cervical Carcinogenesis by Herbal Derivatives.” International Symposium on Translational Cancer Research, Lonavala, Mumbai, December 9-12, 2007.

11. Shirish Shukla, Showket Hussain, Shailja Pande, Prishla Vargheese, Harsimrut kaur, Bhupesh Prusty, Neeraj Jain, Alok Mishra, Gitanjali Bugnait, Sanjay Katiyar, V. Gopalkrishna, Suresh Hedau, Mausumi Bharadwaj, Alok C. Bharti, Bhudev C. Das. “Mapping of Human Papillomaviruses Infections in Cancers and Pre-cancers of Different Organ Sites in India” in 24th International Papillomavirus Conference and Clinical Workshop in Beijing, China.

12. Mausumi Bharadwaj, Vilas Nasare, Suresh Hedau, Showket Hussain, Indu Kohaar, Nisha Thakur, Shirish Shukla, Smitha Asthana, Raj Narain, Alok C Bharti, B C Das. “Prevalence of Human Papillomavirus (HPV) infection among pre-adolescent children in

- 5 -

document.doc

India.” in 24th International Papillomavirus Conference and Clinical Workshop in Beijing, China.

13. Showket Hussain, Shirish Shukla, Rakesh Kumar, Umesh Kumar, Irfana Salam, Shakeel-ul-Rehman, Seemi Farhat Basir, Alok C. Bharti, Mohd. Akbar Bhat, Mushtaq A. Siddiqi, Bhudev C. Das. “The Role of c-Fos and Fos Related Antigen-1 (Fra-1) in the Pathogenesis of Esophageal Carcinoma” in International Symposium on Genomic Instability and Cancer held at Srinagar, July 22-26, 2007.

14. Alok Mishra, Alok C. Bharti, Prishla Varghese and Bhudev C. Das. “HPV infection in oral carcinogenesis: Role of Transcription Factor NF-kB” in ICGEB DNA Tumour Virus Meeting held at ICGEB, Trieste, Italy during 17-22 July 2007.

15. Shukla, S., Hussain, S., Mahata, S., Kumar, R., Joshi, S., Tyagi, A., Mishra, A., Varghese, P., Kaur, H., Pande, S., Hedau, S. Bharti, A.C.,and Das, B.C. (2007) “Development of Rapid, Cost Effective and Sensitive Multiplex PCR Assay for Detection of High Risk HPV Type 16 and 18” at 30th All India Cell Biology Conference, Delhi. 2-4 Feb, 2007

16. Pande, S., Jain, N., Prusty, B.K., Hedau, S. Bharti, A.C., and Das, B.C. (2007) “Molecular Variant Analysis of HPV16 in Cervical Cancer Patients from India” at 30th All India Cell Biology Conference, Delhi. 2-4 Feb, 2007

17. Showket Hussain, Shirish Shukla, Sutapa Mahata, Rakesh Kumar, Abhishek Tyagi, Prishla Varghese, Harsimrut Kaur, Alok Mishra, Suresh Hedau, Alok C Bharti and Bhudev C Das. “Analysis of Promoter Hypermethylation of E-Cadherin Gene in Cervical Cancer”. 26th Annual Convention of Indian Association for Cancer Research and International Symposium on Translational Research in Cancer, Bhubaneswar, Orissa, 17th to 19th January, 2007.

18. Bharti, A.C., Varghese, P., Kaur, H., Mukhtar, U., Shukla, S., Mishra, A., Hussain, S., Mahata, S., Kumar, R., Tyagi, A., Hedau, S. and Das, B.C. (2007) “Role of Transcription Factor STAT3 in Human Papillomavirus 16 (HPV16)-induced cervical carcinogenesis” at 26th Annual Convention of Indian Association for Cancer Research, Bhuvaneshwar, Orrisa.

19. Hedau, S., Kumar, R., Tyagi, A., Hussain, S., Shukla, S., Mishra, A., Mahata, S., Bharti, A.C. and Das, B.C. (2007) “No Evidence of HPV infection in Breast Cancer as revealed by conventional as well as Real-time PCR” at 26th Annual Convention of Indian Association for Cancer Research, Bhuvaneshwar, Orrisa.

20. Kumar, R., Mishra, A., Mahata, S., Joshi, S., Tyagi, A., Hussain, S., Shukla, S., Hedau, S., Bharti, A.C., Chaturvedi, M.M., and Das, B.C. (2007) “Role of Transcription Factor Activator Protein-1 (AP-1) in breast carcinogenesis” at 26th Annual Convention of Indian Association for Cancer Research, Bhuvaneshwar, Orrisa.

21. Kaur, H., Varghese, P., Hussain, S., Kumar, R., Shukla, S., Hedau, S., Bharti, A.C. and Das, B.C. (2006) “Development of Customized Microarrays for Early Diagnosis of Cervical Cancer” at Second Medical Development Congress, New Delhi, India.

22. Prusty, B.K., Kaur, H., Mahata, S., Varghese, P., Mishra, A., Hedau, S., Bharti, A.C. and Das, B.C. (2006) Genes and Genomics of Cervical cancer. New Delhi.

- 6 -

document.doc

23. Prusty, B.K., Kaur, H., Mahata, S., Varghese, P., Mishra, A., Hedau, S., Bharti, A.C. and Das, B.C. (2005) “Fos-related antigen-1 (FRA-1): is it a tumor suppressor or a tumor promoter?” (PP07) at International Symposium on Translational Research: Apoptosis and Cancer. Trivandrum, India.

24. Mishra, A., Bharti, A.C., Saluja, D., and Das, B.C. (2005) “Expression and Cellular Localization of NF-B Superfamily Members in Oral Carcinogenesis” at 24th Annual Convention of Indian Association for Cancer Research and International Symposium on Human Papillomavirus and Cervical Cancer, Noida, India. Abstract published in Indian Journal of Medical Research 121: Suppl 123, Feb 2005

25. Bharti, A.C., Panigrahi, A., Bhaumik, D., Tiwari, S.C., and Mehra, N.K., (2004) “Curcumin (Diferuloylmethane) Downregulates CD4:CD8 Ratio and Expression of Interferon- and Interleukin-4 in T Lymphocytes from Patients Following Renal Transplantation” at 12th International Congress of Immunology and 4th Annual Conference of FOCIS, Montreal, Canada. Abstract published in Clinical and Investigative Medicine 27: Suppl 154D.

26. Bharti, A.C., Reuben, J.M., Weber, D., Alexanian R., Talpaz, M., and Aggarwal, B.B., (2003). Nuclear Factor-B and STAT3 are Constitutively Active in CD138+ Myeloma Cells Derived from Patients and Their Suppression Leads to Apoptosis. 5th Sass International Conference on Emerging Concepts in Leukemia and Lymphoma, New Delhi, India.

27. Zheng, B., Li, Y., Georgakis, G., Bharti, A.C., McConkey, D., Aggarwal, B.B., and Younes. A., (2003). Potentiation of chemotherapy and trail-induced cell death of Hodgkin disease cell line by the proteosome inhibitor PS341. 39th Annual Meeting of American Society of Clinical Oncology, Chicago, Illinois, USA.

28. Bharti, A.C., Donato, N., Singh, S., Aggarwal, B.B., (2003) Nuclear factor-kappa B and signal transducer and activator of transcription-3 as a therapeutic target for multiple myeloma. Trainee Recognition 2003 of The U.T. M.D. Anderson Cancer Center, Houston, Texas, USA.

29. Aggarwal, B.B., Bharti, A.C., Banerjee, S., Aggarwal, S., Ashikawa, K., Shishodia, S., (2003). Nuclear factor-kappa B as a therapeutic target for chemoprevention and chemosensitization. Proceedings of the 22nd Annual Convention of the Indian Association of Cancer Research and International Symposium on Recent Advances in Cancer Causes and Control, Thiruvananthpuram, Kerala, India.

30. Bharti, A.C. and Singh, S.M., (2000). Induction of apoptosis in bone marrow cells by gangliosides produced by a T cell lymphoma. 27th Annual Conference of Indian Immunology Society, Agra, Utter Pradesh, India

31. Shanker, A., Singh, S.M. and Bharti, A.C., (1998). Mechanisms of immunosuppression in a tumor-bearing host. International Symposium on Tumor Immunology of 8th

International Immunology Congress, Calcutta, West Bengal, India.

32. Singh, S.M., Shanker, A., Khare, V. and Bharti, A.C., (1998). Mechanism of immunosuppresion in tumor-bearing host: Induction of apoptosis in thymocytes and bone

- 7 -

document.doc

marrow hematopoietic cells. 6th Brainstorming Sessions in Molecular Immunology of Indian Molecular Immunology Forum, Sariska, Rajasthan, India.

International Conferences and Symposia attended1. International Symposium on Tumor Immunology of 8th International Immunology

Congress, Calcutta, India. 1998.

2. 5th Sass International Conference on Emerging Concepts in Leukemia and Lymphoma, New Delhi, India. December 13-16, 2003.

3. 12th International Congress of Immunology and 4th Annual Conference of FOCIS, Montreal, Canada. July 18-23, 2004.

4. 24th Annual Convention of Indian Association for Cancer Research and International Symposium on Human Papillomavirus and Cervical Cancer, Noida, India. February 9-12, 2005.

5. 2nd International Symposium on Translational Cancer Research, Lonavala, Mumbai, December 9-12, 2007.

National Conferences and Symposia attended

1. 27th Annual Conference of Indian Immunology Society, Agra, 2000.

2. Ranbaxy Science Foundation Symposium, AIIMS, New Delhi, November 28, 2005.

3. Symposium of Indian Association for Cancer Research – Delhi Chapter, AIIMS, New Delhi, November 28, 2005.

4. Living with TRIPS: Innovation of New Health Technologies for the Poor. A symposium conducted by ICMR, New Delhi & MIHR, Oxford, at New Delhi December 4-7, 2005.

5. Organized and participated in a corporate seminar series on “Proteomics: Cutting edge technologies and their applications” at ICPO, NOIDA. July 17, 2006

6. Organized and participated in Minisymposium on “Recent Trends in Translational Cancer Research” at ICPO, NOIDA. September 20th, 2006.

7. Organized a Wet Workshop under the DBT-Multicentric Project on “Development of HPV Diagnostics for Early Detection of Cervical Cancer” March 27-28, 2006

Workshop Participation

1. Participated in 2nd Winter School of Immunology at Trivandrum 2001.

2. Participated in “Safe handling of radioactive materials in research and clinical laboratories” M.D. Anderson Cancer Center, Texas, USA. August 8, 2001.

3. Indo-US Workshop on “Grantsmanship in India” New Delhi, September 6&7, 2004.

4. ICMR-MIHR workshop on “IP and Technology Management in Health” New Delhi, January 23, 2006.

5. NIMS Training workshop on Medical Statistics, New Delhi, January 9-12, 2006.

- 8 -

document.doc

Administrative Assignments

Served as Joint Secretary of 24th Annual Convention of Indian Association of Cancer Research and International Symposium on “Human Papillomavirus and Cervical Cancer” held in the premises of ICPO from February 9-12, 2005.

Serving as Member of the Institutional Technical Committee since 2004.

Serving as Member of the Institutional Purchase Committee since 2004.

Served as Member of the Institutional Non-Smoking Policy Committee since 2004.

Served as Representative of ICPO to the Council’s Technical Committee since 2005.

Compilation, editing and formatting of ICPO’s Annual Report of year 2003-2005.

Compilation of Institute’s 11th Five Year plan document for the year 2007-2012

Appointed as Central Public Information Officer in Basic Sciences of the Institute Since July 2006.

In-charge, Audio-visual Facility of ICPO

Organized a Wet Workshop under the DBT project “Development of HPV Diagnostics for Early Detection of Cervical Cancer”

Organized a corporate seminar series on “Proteomics: Cutting edge technologies and their applications” at ICPO, NOIDA. July 17, 2006

Organized a Minisymposium on “Recent Trends in Translational Cancer Research” at ICPO, NOIDA. September 20th, 2006.

Served as a Member of Scientific Advisory Committee of 26 th Annual Convention of IACR at Bhuvaneshvar.

Compilation, editing and formatting of ICPO’s Annual Report of year 2005-2007.

Ongoing Research ProjectsA. As Principal Investigator:

i. “Role of Transcription Factor STAT3 in Human Papillomavirus 16 (HPV16)-Induced Cervical Carcinogenesis”

Funded by DBT (Rs. 43 Lakhs), Duration: 2007-2010

B. As Co-Investigator:i. Task force project on role of tobacco use in causation of cancer in

North-East India Funded by ICMR (Rs. 40 Lakhs), Duration: 2005-2009

ii. Task force project on role of pesticide exposure in causation of cancer in North-East India

Funded by ICMR (Rs. 14 Lakhs), Duration: 2005-2009

- 9 -

document.doc

iii. Investigation on the clearance of human Papillomavirus infection in uterine cervix by BASANT, a polyherbal vaginal cream and CURCUMIN

Funded by DBT (Rs. 30 Lakhs), Duration: 2007-2010

iv. Development of Regional HPV Laboratory for Monitoring HPV Vaccine Programme

Funded by WHO (US$20,000), Duration: 2007-2009

v. Development of Chimeric Genetic Vaccine against Human Papillomavirus Type 16

Funded by ICMR-DKFZ (Indo-German) (Rs. 33 Lakhs)Duration: 2008-2011

Ph.D. Dissertations under progress

1. Sachin Singla, “Clinical Implications of Circulating DNA and Protein Markers in Lung Cancer”, All India Institute of Medical Sciences (AIIMS), New Delhi. (2006)

2. Shabeena Rehman, “Prevalence and Molecular Characterization of Helicobacter pylori genotypes in patients with duodenal ulcers and gastric carcinoma”. Jamia Millia Islamia, New Delhi. (2006)

3. Showket Hussain, “Cellular and viral gene interaction and their regulation during development of Esophageal cancer”. Jamia Millia Islamia, New Delhi. (2007)

4. Shirish Shukla, “Role of STAT-3 transcription factor in cervical cancer carcinogenesis”, Jamia Millia Islamia, New Delhi. (2007)

5. Dayalu Naik, S.L., “Expression of IL-6 and IFN- cytokines in cervical carcinogenesis”, Kurempu University, Karnataka (2008)

As a Member of Doctoral Committee

6. Neelam Nazmi, All India Institute of Medical Sciences (AIIMS), New Delhi. (2005)

7. Surendra Kumar Sharawat, Biological and clinical significance of proliferative and apoptotic markers in acute myeloid leukemia (AML)” All India Institute of Medical Sciences (AIIMS), New Delhi. (2007)

M.Sc. Project Dissertations completed

1. Ms. Smita Jain, “Detection of high risk Human papillomavirus type 16 & 18 infection in cervical cancer by multiplex PCR.” Department of Biotechnology, IMR, Ghaziabad, U.P. 2006.

2. Ms Urooj Mukhtar, “Role of STAT proteins in Cervical Carcinogenesis”, M.Sc. Biotechnology, Jamia Milia Islamia, Okhla, New Delhi, 2006.

- 10 -

document.doc

3. Ms. Pallavi Gupta, “Analysis of Methylation Pattern in E-Cadherin gene in Cervical Cancer”, M.Sc. Biotechnology, Amity Institute of Biotechnology (AIB), Amity University, Noida. U.P., 2006.

4. Mr. Dipankar Dey, “Expression Profile of AP-1 Transcription Factor in Oral Cancer tissues.” M.Sc Molecular & Human Genetics, Centre of Genomics, Jiwaji University, Gwalior, 2006.

5. Ms. Nidhi Aishvarya, “Analysis of Methylation Pattern of GSTPi and E-Cadherin in Sporadic Breast Cancer”, M.Sc. Microbiology, Dept. of Microbiology, Baraktullah University, Bhopal, 2006.

6. Mr. Saurabh Maru, “To study the Anticancer and Antiviral activity of Bryophyllum pinnata separated leaves extract on cancer cell lines.” M. Pharm. Pharmacology, Dept. of Pharmacology, Krupanidhi College of Pharmacy, Bangalore, 2006.

7. Ms. Aswini Gnanasekaran, “DNA Binding activity of AP-1 transcription factor in Breast Cancer Tissues” M.Sc. Animal Biotechnology, Bharathidasan University, Thiruchirapulli, Tamilnadu, 2006.

8. Mohammed Asad, “Molecular Cloning & Expression of CRPV L1 ORF in Prokaryotic System”, M.Sc. Biotechnology, Jiwaji University, Gwalior, 2006.

9. Mr. Ajay Abraham, “In vivo Expression Pattern of Notch1 and its ligand Jagged1 in breast cancer”, M.Sc. Biotechnology, Cochin university of Science and Technology, Cochin, Kerala. 2007.

10. Ms. Arjita Tripati, “Comparison of URR, E6, E7 & L1 regions in Cervical Cancer” M.Sc. Biotechnology, A.P.S. University, Rewa, M.P., 2007.

11. Ms. Gauri Shishodia, “Mutational analysis of BRCA1, BRCA2 & p53 genes in breast Cancer”. M.Sc. Biotechnology ITS paramedical College, Ghaziabad, CCS university, Meerut U.P., 2007.

12. Ms. Namita Balodi, “Early detection of Cervical Cancer using Paper Smear”, M.Sc. Biotechnology, H.N. B. Garhwal Universiy, Srinagar, Uttaranchal, 2007.

13. Ms. Neetu Sharma, “To analyze the expression pattern of different members of NF-kB family members in breast cancer tissues using immunohistochemistry”. M.Sc. Microbiology, IAMR, Ghaziabad, CCS University, Meerut, 2007.

14. Ms. Shilpi Vajpai, “Role of AP-1 transcription factor in Esophageal Cancer”, M.Sc. Biotechnology, Jiwaji University, Gwalior, 2007.

- 11 -

document.doc

Indian Science Academy Summer fellows

1. Mr. Subhodeep Sarker (BE Biotechnology), Birla Institute of Technology, Mesra, Ranchi, Jharkhand, 2006.

2. Ms. Vinatha Sreeramkumar (M.Sc Immunology and Microbiology), The American college (MKU), Madurai, 2006.

3. Ms. Arif Nisha, (M.Sc. Biotechnology), Alagappa University, Karaikudi, Tamilnadu, 2007.

4. Mr. Kangaraju. P, (M.Sc. Animal Biotechnology), Bharathidasan University, Trichy, Tamilnadu, 2007.

MembershipsIndian Immunology society, India - Life Member since year 1997.

Indian Association for Cancer Research, India - Life Member since year 2004.

Indian Society of Cell Biology, India - Life Member since year 2007

Reviewer of International JournalsCarcinogenesis, Microbes and Infection, Indian Journal of Medical ResearchR

A brief write-up on scientific contributions of the nominee – Dr. Alok Chandra Bharti

Dr. Alok Chandra Bharti has made original contributions to Biomedical Sciences particularly in the field of Cancer Research. During eleven years (1996-2007) of his distinguished research career as a Ph.D. scholar at BHU, then as Post-doctoral Fellow at M.D. Anderson Cancer Center and now as a Senior Research Officer at ICPO, Dr. Bharti published twenty one research papers in high impact journals and books brought out by internationally reputed publishers. A significant portion of these publications is a result of his research carried out in India. He is a brilliant student of Science since beginning with an excellent track record.

Dr. Bharti is already widely known for his work on Curcumin and its use in the treatment of multiple myeloma and associated bone lesions. His pioneer work on multiple myeloma cells from patients showed that transcription factors Nuclear Factor (NF)-B and Signal Transducer and Activator of Transcription (STAT)-3 were constitutively active in cancer cells which acted as essential survival factors. He demonstrated that curcumin could inhibit constitutive and inducible activation of these transcription factors in myeloma cells. He also showed in vitro that curcumin could directly inhibit IB kinase (IKK), a key enzyme involved in activation of NF-B. His recent studies clearly demonstrate that curcumin can also overcome the chemoresistance in the myeloma cells.

His pioneering studies in receptor activator of NF-B ligand (RANKL)-induced bone catabolism, often observed during multiple myeloma and breast cancer, showed a therapeutic potential of curcumin in prevention and treatment of bone lesions. RANKL is a key cytokine in osteoclast development and bone lysis. Recent studies by Dr. Bharti showed that curcumin can block osteoclastogenesis through inhibition of NF-B activation by RANKL. On the basis of the applicability of these studies clinical trials are being formulated at M.D. Anderson Cancer Center to treat multiple myeloma patients.

- 12 -

document.doc

While working on RANKL, Dr. Bharti discovered a new activity associated with it. RANKL was known to be an essential factor for osteoclast and dendritic cell differentiation, function and survival. His studies provided the evidence that RANKL can also suppress cell proliferation and may induce apoptosis. These leading observations were published in high impact journals like JBC, Blood, JI and Apoptosis.

His doctoral research work in tumor-induced immunosuppression described for the first time the role of gangliosides, the molecules shed by the tumor cells results in myelosuppression which is invariably observed in tumor-bearing host irrespective of its, etiology, location or origin. He showed that gangliosides grossly impaired the mature macrophage activity as well as profoundly altered the hematopoietic differentiation pathway of myeloid progenitors and directed them to differentiate into granulocytes instead of monocyte/macrophages. Gangliosides also inhibited the proliferation of bone marrow cells and reduce the viability of hematopoietic precursor cells.

Dr. Bharti joined the Division of Molecular Oncology, Institute of Cytology and Preventive Oncology (ICMR) an autonomous institution of Cancer Research under the Ministry of Health and Family Welfare as a regular senior scientist where he continued his pursuit for excellence in cancer research in the field of cancer prevention and has made significant contribution in the field of cervical, breast and oral cancers as well as cancers that are most prevalent in the Northeast region of the country. Recent studies by Dr. Bharti showed for the first time how presence or absence of HPV may influence the therapeutic strategy, outcome and management of oral cancers. Dr. Bharti is also involved in developing novel strategies for cancer cell-specific targeting of anti-cancer drugs using nano-delivery systems. In addition, he is also associated in establishment of several new high-throughput genomic laboratory for molecular screening and identification of new and more robust molecular tumor markers.

- 13 -